NBY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NovaBay Pharmaceuticals Inc (NBY) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock is undergoing significant changes, including a rebranding and a shift in business direction, which introduces uncertainty. Additionally, the company's financial performance is weak, with declining net income and EPS. The technical indicators do not provide a clear entry signal, and there are no strong positive catalysts to support a long-term investment decision.
The MACD is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 59.279, and moving averages are converging, suggesting no clear trend. Key support and resistance levels are at 1.444 (pivot), 1.719 (R1), and 1.169 (S1). Overall, technical indicators do not signal a strong buy opportunity.
The company is rebranding to align with its new business direction, which could attract investor interest in the future. Additionally, the company holds a significant amount of SKY tokens, which may provide potential upside if the token value increases.
The recent $100 million stock sale agreement has caused market caution. The company's financial performance is weak, with declining net income and EPS. The rebranding and shift in business direction introduce uncertainty about the company's future prospects.
In 2025/Q3, revenue remained flat at $521,000 YoY, while net income dropped significantly by -41.68% YoY to -$1,293,000. EPS also fell sharply by -88.54% YoY to -1.1. Gross margin increased slightly to 8.06%, but overall financial performance remains poor.
No recent analyst ratings or price target changes are available for NovaBay Pharmaceuticals.
